Compare KNSA & SLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNSA | SLM |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | United Kingdom | United States |
| Employees | N/A | 1788 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.2B |
| IPO Year | 2018 | N/A |
| Metric | KNSA | SLM |
|---|---|---|
| Price | $55.11 | $23.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $60.86 | $31.09 |
| AVG Volume (30 Days) | 492.0K | ★ 2.4M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.48 | $3.35 |
| Revenue Next Year | $17.87 | $5.68 |
| P/E Ratio | $204.43 | ★ $6.91 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $26.27 | $17.77 |
| 52 Week High | $59.87 | $34.25 |
| Indicator | KNSA | SLM |
|---|---|---|
| Relative Strength Index (RSI) | 63.62 | 57.53 |
| Support Level | $40.67 | $21.00 |
| Resistance Level | $59.87 | $23.09 |
| Average True Range (ATR) | 1.83 | 0.76 |
| MACD | 0.59 | 0.10 |
| Stochastic Oscillator | 91.10 | 76.96 |
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.